Studies on the structure of the complex of the boron neutron capture therapy drug, L-p-boronophenylalanine, with fructose and related carbohydrates: Chemical and 13C NMR evidence for the β-D-fructofuranose 2,3,6-(p-phenylalanylorthoboronate) structure
Corresponding Author
Brian K. Shull
Glycosyn Pharmaceuticals, Inc., Cary, North Carolina 27513
Glycosyn Pharmaceuticals, Inc., Cary, North Carolina 27513Search for more papers by this authorDavid E. Spielvogel
New Concept Therapeutics, Inc., Cary, North Carolina 27513
Search for more papers by this authorGerald Head
New Concept Therapeutics, Inc., Cary, North Carolina 27513
Search for more papers by this authorRamesh Gopalaswamy
Glycosyn Pharmaceuticals, Inc., Cary, North Carolina 27513
Search for more papers by this authorSabapathy Sankar
Department of Chemistry, North Carolina State University, Raleigh, NC 27695
Search for more papers by this authorKevin Devito
Glycosyn Pharmaceuticals, Inc., Cary, North Carolina 27513
Search for more papers by this authorCorresponding Author
Brian K. Shull
Glycosyn Pharmaceuticals, Inc., Cary, North Carolina 27513
Glycosyn Pharmaceuticals, Inc., Cary, North Carolina 27513Search for more papers by this authorDavid E. Spielvogel
New Concept Therapeutics, Inc., Cary, North Carolina 27513
Search for more papers by this authorGerald Head
New Concept Therapeutics, Inc., Cary, North Carolina 27513
Search for more papers by this authorRamesh Gopalaswamy
Glycosyn Pharmaceuticals, Inc., Cary, North Carolina 27513
Search for more papers by this authorSabapathy Sankar
Department of Chemistry, North Carolina State University, Raleigh, NC 27695
Search for more papers by this authorKevin Devito
Glycosyn Pharmaceuticals, Inc., Cary, North Carolina 27513
Search for more papers by this authorAbstract
The complex of L-L-boronophenylalanine (L-p-BPA) with fructose has been used for the past 5 years in clinical trials of boron neutron capture therapy to treat both melanoma and glioblastoma multiforme. However, the structure of this complex in water buffered at physiologic pH has not been established. In the 1H NMR spectra (D2O buffered at pD 7.4) of the complex of L-p-BPA with various carbohydrates, the upfield chemical shifts of the aromatic protons of L-p-BPA confirm that the boron atom is negatively charged and tetrahedral. In the 13C NMR spectrum of the complex of L-p-BPA with U-13C labeled fructose, the chemical shifts and 1JCC coupling constants are consistent with fructose adopting the β-D-fructofuranose form. In addition, the 1JCC coupling constants along with the binding constants measured for L-p-BPA with a series of monosaccharides and disaccharides seem to suggest that the β-D-fructofuranose 2,3,6-(p-phenylalanylorthoboronate) structure strongly predominates, with free L-p-BPA and fructose the only other species detected. © 2000 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 89: 215–222, 2000
REFERENCES AND NOTES
- 1Locher GL. 1936. Biological effects and therapeutic possibilities of neutrons. Am J Roentgenol Radiat Ther 36: 1–36.
- 2(a) Javid M, Brownell GL, Sweet WH. 1952. The possible use of neutron-capture isotopes such as boron-10 in the treatment of neoplasms. II. Computation of the radiation energy and estimates of effects in normal and neoplasmic brain. J Clin Invest 31: 603–610 (b) Sweet WH. 1951. The uses of nuclear disintegration in the diagnosis and treatment of brain tumor. N Engl J Med 245: 875–878 (c) Sweet WH, Javid M. 1952. The possible use of neutron-capturing isotopes such as boron10 in the treatment of neoplasms. I. Intracranial tumors. J Neurosurg 9: 200–209.
- 3(a) Shi J-LA, Brugger RM. 1992. Gadolinium as a neutron capture therapy agent. Med Phys 19: 733–743 (b) Miller AV, Horton JL. 1997. Advantage of using Cf-252 combined with Gd-157 for treatment of bulky tumors. In: B Larsson, J Crawford, R Weinreich, editors. Advances in neutron capture therapy, Vol II. New York: Elsevier Science. pp 545–546.
- 4(a) Shpikalov VL, Atkocius VB, Valuckas KK. 1991. The application of 252Cf in contact neutron therapy of malignant tumors at the Scientific Research Institute of Oncology in Vilnius, Lithuania. Nucl Sci Appl 4: 419–424 (b) Rebuchin US, Chehonadski VN. 1987. Radiobiological considerations of 252Cf brachiotherapy. Med Radiol 6(32): 92–98 (c) Beach JL, Shory CB, et al. 1990. Boron neutron capture enhancement of 252Cf brachiotherapy. Int J Radiat Oncol Biol Phys 18: 1421–1427.
- 5(a) Gubernator K, Moret H. 1968. Evaluation of the 10B(n,α) cross section and branching ratio. Report EUR-3950e. Brussels: EURATOM (b) Kobayashi T, Kanda K. 1982. Analytical calculation of boron-10 dosage in cell nucleus for neutron capture therapy. Radiat Res 91: 77–94.
- 6Asbury AK, Ojeann RG, Nielsen SL, Sweet WH. 1972. Neuropathologic study of fourteen cases of malignant brain tumor treated by boron-10 slow neutron capture radiation. J Neuropathol Exp Neurol 31: 278–303.
- 7Barth RF, Soloway AH, Fairchild RG. 1990. Boron neutron capture therapy of cancer. Cancer Res 50: 1061–1070.
- 8Hatanaka H, Kamano S, Amano K, Hojo S, Sano K, Egawa S, Yasukochi H. 1896. Clinical experience of boron-neutron capture therapy for gliomas-a comparison with conventional chemo-immuno-radiotherapy. In: H Hatanaka, editor. Boron neutron capture therapy for tumors. Niigata, Japan: Nishimura Co., Ltd. pp 349–378.
- 9Mishima Y, Ichihashi M, Tsui M, Hatta S, Ueda M, Honda C, Susuki T. 1989. Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B compound. Lancet 2: 388–389.
- 10For an excellent review of boron analogs of biomolecules for BNCT, see: Morin C. 1994. The chemistry of boron analogues of biomolecules. Tetrahedron 50: 12521–12569 and references cited therein.
- 11(a) Ichihashi M, Nakanishi T, Mishima Y. 1982. Specific killing effect of 10B1-para-boronophenylalanine in thermal neutron capture therapy of malignant melanoma: In vitro radiobiological evaluation. J Invest Dermatol 78: 215–218. (b) Yoshino KM, Okamoto H, Kakihana T, Mori Y, Mishima Y, Ichihashi M, Tsuji M, Nakanishi T. 1986. Chemical assay of boron and its distribution in melanoma-bearing subjects. In Proceedings of the 2nd International Symposium on Neutron Capture Therapy. pp 291–302.
- 12(a) Aronoff S, Chen TC, Cheveldayoff M. 1975. Complexation of D-glucose with borate. Carbohydr Res 40: 299–309 (b) van Duin M, Peters JA, Kieboom APG, van Bekkum H. 1984. Studies on borate esters I. Tetrahedron 40: 2901–2911 (c) van Duin M, Peters JA, Kieboom APG, van Bekkum H. 1985. Studies on borate esters II. Tetrahedron 41: 3411–3421 (d) Verchere JF, Hlaibi M. 1987. Stability constants of borate complexes of oligosaccharides. Polyhedron 6: 1415–1420 (e) Dawber JG, Green AIE, Dawber JC, Gabrail SA. 1988. Polarimetric and 11B and 13C nuclear magnetic resonance study of the reaction of the tetrahydroxyborate ion with polyols and carbohydrates. J Chem Soc, Faraday Trans 1 84(1): 41–56 (f) Chapelle S, Verchere J-FA. 1988. 11B and 13C NMR determination of the structures of borate complexes of pentoses and related sugars. Tetrahedron 44: 4469–4482.
- 13(a) Kuivila HG, Keough AH, Soboczenski EJ. 1954. Areneborates from diols and polyols. J Org Chem 19: 780–783 (b) Lorand JP, Edwards JO. 1959. Polyol complexes and structure of the benzeneborate ion. J Org Chem 24: 769–774 (c) Wood PJ, Siddiqui IR. 1974. Synthesis, P.M.R. and mass spectra of some boronic esters of carbohydrates. Carbohydr Res 36(a): 247–256.
- 14(a) Mori Y, Suzuki A, Yoshino K, Kakihana H. 1989. Complex formation of p-boronophenylalanine with some monosaccharides. Pigment Cell Res 2:273–277 (b) Yoshino K, Suzuki A, Mori Y, Kakihana H, Honda C, Mishima Y, Kobayashi T, Kanda K. 1989. Improvement of solubility of p-boronophenylalaine by complex formation with monosaccharides. Strahlenther Onkol 165: 127–129 (c) Kinoshita Y, Yoshino K, Mori Y, Kakihan H, Mishima Y. 1992. Complex formation of phenylboronic acid derivatives with aldopentoses and oligosaccharides. In: BJ Allen, DE Moore, BV Harrington, editors. Progress in neutron capture therapy for cancer. New York: Plenum. pp 243–246 (d) LaHann TR. Method for enhancing the solubility of the boron delivery drug, boronophenylalnine (BPA). US Patent No. 5,492,900. Issued 2/20/96.
- 15(a) Honda C, Shiono M, Wadabayashi N, Ichihashi M, Mishima Y, Koybayashi T, Kanda K, Hori Y, Yoshino K. 1992. Increased selective 10B-uptake by malignant melanoma using systematic administration of 10B-BPA-fructose complex. In BJ Allen, DE Moore, BV Harrington, editors. Progress in neutron capture therapy for cancer. New York: Plenum. pp 421–424.
10.1007/978-1-4615-3384-9_93 Google Scholar(b) Mallesch J, Moore DE, Allen BJ, McCarthy WH, Jones R, Stening WA. 1993. The biodistribution of p-boronophenylalanine-fructose in human patients with glioma and metastatic melanoma. In: AH Soloway, RF Barth, DE Carpenter, editors. Advances in neutron capture therapy. New York: Plenum. pp 735–73810.1007/978-1-4615-2978-1_146 Google Scholar(c) Matalka KZ, Baily MQ, Barth RF, Staubus AE, Soloway AH, Moeschberger ML, Coderre JA, Rofstad EK. 1993. Boron neutron capture therapy of intracerebral melanoma using boronphenylalanine as a capture agent. Cancer Res 53: 3308–3313.
- 16(a) Snyder HR, Reedy AJ, Lennarz WJ. 1958. Synthesis of aromatic boronic acids. Aldehydo boronic acids and a boronic acid analog of tyrosine. J Am Chem Soc 80: 835–838.
- 17Gianotto AK, Bauer WF. 1992. Optical purity determination of D,L-boronophenylalanine by high performance liquid chromatography with a chiral mobile phase. In: BJ Allen, DE Moore, BV Harrington, editors. Progress in neutron capture therapy for cancer. New York: Plenum. pp 247–250.
10.1007/978-1-4615-3384-9_53 Google Scholar
- 18Shull BK, Spielvogel DE, Head G. U. S. patent pending.
- 19Coderre JA, Button TM, Micca PL, Fisher CD, Nawrocky MM, Hungyuan BL. 1994. Neutron capture therapy of the 9L rat gliosarcoma using the p-boronophenylalanine-fructose complex. Int J Radiat Oncol Biol Phys 30: 643–652.
- 20(a) van den Berg R, Peters JA, van Bekkum H. 1994. The structure and (local) stability constants of borate esters of mono- and di-saccharides as studied by 11B and 13C NMR spectroscopy. Carbohydr Res 253: 1–12
(b) Pelmore H, Symons MCR. 1986. NMR studies of complexes formed by D-fructose and borate ions in aqueous solution. Carbohydr Res 155: 206–211
(c) Schnieder B, Lichtenthaler W, Steinle G, Schiweck H. 1985. Distribution of furanoid and pyranoid tautomers of D-fructose in water, dimethyl sulfoxide, and pyridine via 1H NMR intensities of anomeric hydroxy groups in [D6]DMSO. Liebigs Ann Chem, 2443–2453.
10.1002/jlac.198519851213 Google Scholar(d) Goux WJ. 1985. complex isomerization of ketoses: A 13C NMR study of the base-catalyzed ring-opening and ring-closing rates of D-fructose isomers in aqueous solution. J Am Chem Soc 107: 4320–4327.
- 21Norrild JC, Eggert H. 1996. Boronic acids as fructose sensors. Structure determination of the complexes involved using 1Jcc coupling constants. J Chem Soc Perkin Trans 2 2583–2588.
- 22(a) Norrild JC, Eggert H. 1995. Evidence for mono- and bisdentate borate complexes of glucose in the furanose form. Application of 1JC-C coupling constants as a structural probe. J Am Chem Soc 117: 1479–1484 (b) Duker JM, Serianni AS. 1993. (13C)-Substituted sucrose: 13C-1H and 13C-13C spin coupling constants to assess furanose ring and glycosidic bond conformations in aqueous solution. Carbohydr Res 249: 281–303 (c) Snyder JR, Serianni AS. 1987. Synthesis and NMR-spectral analysis of unenriched and [1-13C]-enriched 5-deoxypentoses and 5-O-methylpentoses. Carbohydr Res 163: 169–188 (d) Krivdin LB, Kalabin GA. 1989. Structural applications of one-bond carbon-carbon spin-spin coupling constants. Progr NMR Spectroscopy 21: 293–448.
- 23Gagnaire D, Reutenauer H, Taravel F. 1979. Etude RMN 13C d'un dérivé uniformément enrichi en 13C. Signe des valeurs des constantes de couplage observées. Org Magn Reson 12: 679–683.
- 24Carmichael I, Chipman DM, Podlasek CA, Serianni AS. 1993. Torsional effects on the one-bond 13C-13C spin coupling constant in ethylene glycol: insights into the behavior of 1JCC in carbohydrates. J Am Chem Soc 117: 10863–10870.
- 25 Regression analysis using CDC of the first six compounds listed in Table III provided the following chemical shifts (with confidence limits in parentheses): C1, 67.8 (3.0); C2, 112.8 (5.6); C3, 87.3 (4.9); C4, 81.0 (4.3); C5, 88.5 (5.6); C6, 67.3 (1.1) ppm.
- 26Bates RG, Bower VE. 1956. Alkaline solutions for pH control. Anal Chem 28: 1322–1324.